Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OLG002
MIFTS: 60

Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oligodendroglioma

About this section

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 53 59 29 55 6 44 15 73
Oligodendroglial Neoplasm 12 73
Well Differentiated Oligodendroglioma 73
Oligodendroglial Tumors 55
Oligodendroglial Tumor 12

Characteristics:

Orphanet epidemiological data:

59
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 44 D009837
SNOMED-CT 68 73348003
Orphanet 59 ORPHA251627
UMLS via Orphanet 74 C0028945
ICD10 via Orphanet 34 C71.9
Sources

Summaries for Oligodendroglioma

About this section
NIH Rare Diseases : 53 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. Recurrent tumors may need additional surgery, radiation and chemotherapy.

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to adult oligodendroglioma and childhood oligodendroglioma. An important gene associated with Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Carmustine and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Sources

Related Diseases for Oligodendroglioma

About this section

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 adult oligodendroglioma 33.8 IDH1 IDH2
2 childhood oligodendroglioma 33.7 GFAP IDH1 OLIG2 SYP TP73
3 anaplastic oligodendroglioma 33.4 CDKN2A CDKN2C EGFR GFAP IDH2 MGMT
4 oligoastrocytoma 33.4 GFAP IDH2 MGMT
5 glioma susceptibility 1 33.3 GFAP IDH1 IDH2 TP53
6 glioma 31.6 CDKN2A EGFR IDH1 IDH2 PDGFRA POT1
7 dysembryoplastic neuroepithelial tumor 30.8 GFAP IDH1 SYP
8 central neurocytoma 30.7 ENO2 GFAP SYP
9 teratoma 30.6 ENO2 GFAP SYP TP53
10 extraventricular neurocytoma 30.6 GFAP IDH1 SYP
11 clear cell ependymoma 30.5 ENO2 GFAP SYP
12 ependymoma 30.4 EGFR ENO2 GFAP MGMT SYP TP73
13 cystic teratoma 30.4 ENO2 GFAP SYP TP53
14 mixed glioma 30.2 GFAP IDH1 PDGFRA TP53
15 gemistocytic astrocytoma 30.2 GFAP IDH2 PTEN
16 adult astrocytic tumour 30.2 IDH1 IDH2 PTEN
17 ganglioglioma 30.2 ENO2 GFAP SYP TP53
18 angiocentric glioma 30.1 GFAP IDH1 SYP
19 pleomorphic xanthoastrocytoma 30.1 GFAP IDH1 MGMT SYP TP53
20 astroblastoma 30.1 ENO2 GFAP SYP
21 lynch syndrome 30.1 CDKN2A EGFR MGMT TP53
22 gliosarcoma 30.0 EGFR ENO2 GFAP IDH1 MGMT PTEN
23 adenocarcinoma 29.9 CDKN2A EGFR PTEN TP53
24 fibrillary astrocytoma 29.9 GFAP IDH1 IDH2 MGMT TP53
25 glioblastoma 29.9 CDKN2A CDKN2B EGFR IDH1 IDH2 MGMT
26 cerebellar liponeurocytoma 29.9 ENO2 GFAP OLIG2 SYP TP53
27 juvenile pilocytic astrocytoma 29.8 CDKN2A ENO2 GFAP MBP TP53
28 nervous system disease 29.8 ENO2 GFAP MBP SYP TP53
29 myeloma, multiple 29.8 CDKN2A IDH1 IDH2 TP53
30 hydrocephalus 29.8 ENO2 GFAP MBP PTEN SYP TP53
31 neurilemmoma 29.7 ENO2 GFAP PDGFRA
32 glioblastoma multiforme 29.5 CDKN2A EGFR GFAP IDH1 MGMT PDGFRA
33 brain cancer 28.8 EGFR ENO2 GFAP IDH1 IDH2 MBP
34 medulloblastoma 28.7 CDKN2B EGFR ENO2 GFAP IDH1 MGMT
35 grade iii astrocytoma 28.6 CDKN2A CDKN2B EGFR GFAP IDH2 MGMT
36 spinal cord oligodendroglioma 12.2
37 brain oligodendroglioma 12.2
38 corpus callosum oligodendroglioma 12.2
39 mixed oligodendroglioma-astrocytoma 12.1
40 mixed astrocytoma-ependymoma-oligodendroglioma 12.0
41 glioma susceptibility 2 11.0
42 glioma susceptibility 3 11.0
43 glioma susceptibility 9 11.0
44 astrocytoma 10.5
45 cytogenetically normal acute myeloid leukemia 10.4 IDH1 IDH2
46 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
47 melanotic medulloblastoma 10.4 ENO2 GFAP
48 pancreatic somatostatinoma 10.4 ENO2 SYP
49 sensory organ benign neoplasm 10.4 ENO2 SYP
50 cutaneous ganglioneuroma 10.4 ENO2 SYP

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma
Sources

Symptoms & Phenotypes for Oligodendroglioma

About this section

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.98 EGFR
2 Decreased viability GR00173-A 9.98 PDGFRA
3 Decreased viability GR00221-A-1 9.98 CDKN2A CDKN2C EGFR PDGFRA POT1
4 Decreased viability GR00221-A-3 9.98 CDKN2A PDGFRA POT1
5 Decreased viability GR00221-A-4 9.98 CDKN2A EGFR PDGFRA POT1
6 Decreased viability GR00301-A 9.98 CDKN2C
7 Decreased viability GR00342-S-2 9.98 CDKN2C
8 Decreased viability GR00402-S-2 9.98 CDKN2A CDKN2C EGFR PDGFRA POT1
9 Decreased viability in esophageal squamous lineage GR00235-A 9.36 CDKN2A CDKN2C GFAP IDH1 IDH2 MBP

MGI Mouse Phenotypes related to Oligodendroglioma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDKN2A CDKN2B CDKN2C EGFR ENO2 GFAP
2 growth/size/body region MP:0005378 10.39 CDKN2A CDKN2C EGFR ENO2 GFAP IDH1
3 behavior/neurological MP:0005386 10.37 CDKN2A CDKN2C ENO2 GFAP MBP OLIG1
4 mortality/aging MP:0010768 10.36 CDKN2A CDKN2B CDKN2C EGFR GFAP IDH1
5 homeostasis/metabolism MP:0005376 10.34 CDKN2A CDKN2B CDKN2C EGFR GFAP IDH1
6 immune system MP:0005387 10.26 CDKN2A CDKN2B CDKN2C EGFR GFAP IDH1
7 nervous system MP:0003631 10.24 CDKN2A CDKN2C EGFR ENO2 GFAP MBP
8 endocrine/exocrine gland MP:0005379 10.22 CDKN2A CDKN2B CDKN2C EGFR MGMT NKX2-2
9 embryo MP:0005380 10.14 CDKN2A EGFR NKX2-2 PDGFRA POT1 PTEN
10 neoplasm MP:0002006 10.14 CDKN2A CDKN2B CDKN2C EGFR IDH2 MGMT
11 integument MP:0010771 10.06 CDKN2A CDKN2B CDKN2C EGFR OLIG1 PDGFRA
12 no phenotypic analysis MP:0003012 9.92 CDKN2A CDKN2B EGFR MGMT OLIG2 PDGFRA
13 reproductive system MP:0005389 9.85 CDKN2A CDKN2B CDKN2C EGFR MBP NKX2-2
14 respiratory system MP:0005388 9.7 CDKN2A CDKN2C EGFR ENO2 IDH1 MGMT
15 pigmentation MP:0001186 9.65 CDKN2A EGFR PDGFRA PTEN TP53
16 vision/eye MP:0005391 9.23 CDKN2A EGFR GFAP MBP OLIG2 PTEN
Sources

Drugs & Therapeutics for Oligodendroglioma

About this section

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
3
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
7
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
8
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
9
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
10
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
11
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
12
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
13
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
21
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
22
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
23
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
24
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
25
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
27
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
28 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
29 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
38 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
39 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Folate Phase 3,Phase 2,Phase 1,Not Applicable
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
46 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
47 Liver Extracts Phase 3,Phase 2,Phase 1
48 Antiemetics Phase 3,Phase 2,Phase 1
49 Emetics Phase 3,Phase 2
50 Keratolytic Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
8 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
11 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
12 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
13 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
14 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
15 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
16 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
18 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
19 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
20 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
21 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
22 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
23 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status NCT02238496 Phase 2 Perifosine;Temsirolimus
24 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
25 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
26 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
27 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
28 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
29 Radiation Therapy in Treating Young Patients With Gliomas Unknown status NCT00238264 Phase 2
30 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
31 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
32 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
33 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
34 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
35 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
36 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
37 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
38 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
39 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
40 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
41 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
42 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
43 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
44 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
45 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
46 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
47 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
48 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
49 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
50 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2 Temozolomide

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Sources

Genetic Tests for Oligodendroglioma

About this section

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 29
Sources

Anatomical Context for Oligodendroglioma

About this section

MalaCards organs/tissues related to Oligodendroglioma:

41
Brain, Spinal Cord, Temporal Lobe, Bone, T Cells, Bone Marrow, Breast
Sources

Publications for Oligodendroglioma

About this section

Articles related to Oligodendroglioma:

(show top 50) (show all 717)
# Title Authors Year
1
Absence of 1p/19q codeletion in oligodendroglioma-like areas of pilocytic astrocytomas. ( 29595124 )
2018
2
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. ( 29131101 )
2018
3
Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. ( 29902567 )
2018
4
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. ( 29192869 )
2018
5
Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas. ( 29746652 )
2018
6
Focal Cortical Dysplasia Type IIIb with Oligodendroglioma in a Seizure-Free Patient. ( 29429417 )
2018
7
Cerebellar Peduncle Localized Oligodendroglioma: A Case Report and Review of the Literature. ( 29438788 )
2018
8
Chronic Scalp Ulcer 35 Years after Skull Trepanation Surgery and Radiotherapy for Oligodendroglioma: A Further Example of Immunocompromised Cutaneous Districts. ( 29483982 )
2018
9
Enchondromatosis-associated oligodendroglioma: case report and literature review. ( 29224049 )
2018
10
Oligodendroglioma Cells Lack Glutamine Synthetase and Are Auxotrophic for Glutamine, but Do not Depend on Glutamine Anaplerosis for Growth. ( 29642388 )
2018
11
A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum? ( 29954769 )
2018
12
Holocord oligodendroglioma with intracranial extension in a young adult: a case report and review of literature. ( 29390865 )
2018
13
Tumour-to-Tumour Metastasis Phenomenon: Metastatic Prostatic Adenocarcinoma within an Anaplastic Oligodendroglioma in the Brain of a Dog. ( 30502799 )
2018
14
Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. ( 30018130 )
2018
15
Anaplastic oligodendroglioma with leptomeningeal dissemination in a french bulldog. ( 30185721 )
2018
16
Multiple Extraneural Metastases of Anaplastic Oligodendroglioma. ( 30283558 )
2018
17
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( 30289152 )
2018
18
Anaplastic oligodendroglioma metastasizing to the bone marrow: A unique case report and literature review. ( 30526175 )
2018
19
Grade II and III Oligodendroglioma and Astrocytoma. ( 30072066 )
2018
20
The effects of tumor size and postoperative radiotherapy for patients with adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma: A population-based and propensity score matched study. ( 30378290 )
2018
21
MRI based texture analysis to classify low grade gliomas into astrocytoma and 1p/19q codeleted oligodendroglioma. ( 30465868 )
2018
22
Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival. ( 29992076 )
2018
23
The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. ( 30206763 )
2018
24
Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. ( 30246385 )
2018
25
Erratum: Author Correction: Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". ( 30202790 )
2018
26
Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted. ( 30210430 )
2018
27
Increased HSPG2 expression independently predicts poor survival in patients with oligoastrocytoma and oligodendroglioma. ( 30402850 )
2018
28
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. ( 30417117 )
2018
29
The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage. ( 30424475 )
2018
30
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
31
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
32
Diffuse Infiltrating Oligodendroglioma and Astrocytoma. ( 28640702 )
2017
33
Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. ( 28900829 )
2017
34
MR textural analysis on T<sub>2</sub>FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification. ( 29140606 )
2017
35
A very rare spinal cord tumor primary spinal oligodendroglioma: A review of sixty cases in the literature. ( 29021677 )
2017
36
Identification and targeting of an FGFR fusion in a pediatric thalamic &amp;quot;central oligodendroglioma&amp;quot;. ( 29872711 )
2017
37
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
38
Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma. ( 28469969 )
2017
39
Multicentric high grade oligodendroglioma: a rare entity. ( 29078728 )
2017
40
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. ( 28498059 )
2017
41
Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. ( 28550371 )
2017
42
Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma. ( 28894952 )
2017
43
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. ( 28384867 )
2017
44
Cerebellar Cystic Oligodendroglioma in a Young Adult. ( 28694642 )
2017
45
Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. ( 28126746 )
2017
46
CNS cancer: Tracing stem cells in oligodendroglioma. ( 27874063 )
2017
47
Pinpointing Cancer Stem Cells in Oligodendroglioma. ( 27864226 )
2017
48
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
49
Pica in a Child with Anterior Cingulate Gyrus Oligodendroglioma: Case Report. ( 28704833 )
2017
50
IMAGING DIAGNOSIS -ANTEMORTEM DETECTION OF OLIGODENDROGLIOMA &amp;quot;CEREBROSPINAL FLUID DROP METASTASES&amp;quot; IN A DOG BY SERIAL MAGNETIC RESONANCE IMAGING. ( 28176389 )
2017
Sources

Variations for Oligodendroglioma

About this section

ClinVar genetic disease variations for Oligodendroglioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
2 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 6867)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6959574 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 5
2 COSM6959528 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 5
3 COSM5981027 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 5
4 COSM6912189 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 5
5 COSM2178900 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 5
6 COSM6969075 TSHR central nervous system,brain,glioma,anaplastic c.1493G>A p.G498D 14:81143551-81143551 5
7 COSM6969076 TSC2 central nervous system,brain,glioma,anaplastic c.3124C>T p.P1042S 16:2079189-2079189 5
8 COSM6946774 TSC2 central nervous system,brain,glioma,anaplastic c.574G>T p.D192Y 16:2055494-2055494 5
9 COSM6959458 TSC1 central nervous system,brain,glioma,anaplastic c.913+1G>A p.? 9:132912281-132912281 5
10 COSM10790 TP53 central nervous system,brain,glioma,anaplastic c.455C>T p.P152L 17:7675157-7675157 5
11 COSM44829 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 17:7675209-7675209 5
12 COSM11224 TP53 central nervous system,brain,glioma,anaplastic c.394A>C p.K132Q 17:7675218-7675218 5
13 COSM10659 TP53 central nervous system,brain,glioma,anaplastic c.817C>T p.R273C 17:7673803-7673803 5
14 COSM10648 TP53 central nervous system,brain,glioma,anaplastic c.524G>A p.R175H 17:7675088-7675088 5
15 COSM44693 TP53 central nervous system,brain,glioma,anaplastic c.707A>C p.Y236S 17:7674256-7674256 5
16 COSM10651 TP53 central nervous system,brain,glioma,anaplastic c.530C>G p.P177R 17:7675082-7675082 5
17 COSM11133 TP53 central nervous system,brain,glioma,anaplastic c.725G>C p.C242S 17:7674238-7674238 5
18 COSM10663 TP53 central nervous system,brain,glioma,anaplastic c.916C>T p.R306* 17:7673704-7673704 5
19 COSM43697 TP53 central nervous system,brain,glioma,anaplastic c.832C>A p.P278T 17:7673788-7673788 5
20 COSM10768 TP53 central nervous system,brain,glioma,anaplastic c.535C>T p.H179Y 17:7675077-7675077 5
21 COSM43742 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 17:7675193-7675193 5
22 COSM44240 TP53 central nervous system,brain,glioma,anaplastic c.514G>T p.V172F 17:7675098-7675098 5
23 COSM44327 TP53 central nervous system,brain,glioma,anaplastic c.518T>C p.V173A 17:7675094-7675094 5
24 COSM10891 TP53 central nervous system,brain,glioma,anaplastic c.814G>A p.V272M 17:7673806-7673806 5
25 COSM46287 TP53 central nervous system,brain,glioma,anaplastic c.557A>G p.D186G 17:7675055-7675055 5
26 COSM10645 TP53 central nervous system,brain,glioma,anaplastic c.527G>T p.C176F 17:7675085-7675085 5
27 COSM43545 TP53 central nervous system,brain,glioma,anaplastic c.503A>G p.H168R 17:7675109-7675109 5
28 COSM10777 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 17:7674248-7674248 5
29 COSM44945 TP53 central nervous system,brain,glioma,anaplastic c.672G>C p.E224D 17:7674859-7674859 5
30 COSM11188 TP53 central nervous system,brain,glioma,anaplastic c.412G>C p.A138P 17:7675200-7675200 5
31 COSM10750 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 17:7675122-7675122 5
32 COSM10667 TP53 central nervous system,brain,glioma,anaplastic c.646G>A p.V216M 17:7674885-7674885 5
33 COSM6906 TP53 central nervous system,brain,glioma,anaplastic c.672+1G>A p.? 17:7674858-7674858 5
34 COSM43747 TP53 central nervous system,brain,glioma,anaplastic c.872A>G p.K291R 17:7673748-7673748 5
35 COSM43843 TP53 central nervous system,brain,glioma,anaplastic c.817C>G p.R273G 17:7673803-7673803 5
36 COSM10887 TP53 central nervous system,brain,glioma,anaplastic c.833C>G p.P278R 17:7673787-7673787 5
37 COSM43947 TP53 central nervous system,brain,glioma,anaplastic c.614A>G p.Y205C 17:7674917-7674917 5
38 COSM43753 TP53 central nervous system,brain,glioma,anaplastic c.560-1G>A p.? 17:7674972-7674972 5
39 COSM43846 TP53 central nervous system,brain,glioma,anaplastic c.487T>C p.Y163H 17:7675125-7675125 5
40 COSM44215 TP53 central nervous system,brain,glioma,anaplastic c.533A>C p.H178P 17:7675079-7675079 5
41 COSM11196 TP53 central nervous system,brain,glioma,anaplastic c.734G>T p.G245V 17:7674229-7674229 5
42 COSM44623 TP53 central nervous system,brain,glioma,anaplastic c.487T>A p.Y163N 17:7675125-7675125 5
43 COSM44633 TP53 central nervous system,brain,glioma,anaplastic c.583A>T p.I195F 17:7674948-7674948 5
44 COSM44910 TP53 central nervous system,brain,glioma,anaplastic c.403T>A p.C135S 17:7675209-7675209 5
45 COSM43743 TP53 central nervous system,brain,glioma,anaplastic c.914A>G p.K305R 17:7673706-7673706 5
46 COSM11451 TP53 central nervous system,brain,glioma,anaplastic c.672G>T p.E224D 17:7674859-7674859 5
47 COSM44570 TP53 central nervous system,brain,glioma,anaplastic c.332T>G p.L111R 17:7676037-7676037 5
48 COSM44393 TP53 central nervous system,brain,glioma,anaplastic c.821T>C p.V274A 17:7673799-7673799 5
49 COSM44053 TP53 central nervous system,brain,glioma,anaplastic c.656C>G p.P219R 17:7674875-7674875 5
50 COSM43679 TP53 central nervous system,brain,glioma,anaplastic c.531C>T p.P177P 17:7675081-7675081 5

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors
Sources

Expression for Oligodendroglioma

About this section
Search GEO for disease gene expression data for Oligodendroglioma.
Sources

Pathways for Oligodendroglioma

About this section

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.79 CDKN2A EGFR PDGFRA PTEN TP53
2
Pathways in cancer 37
12.71 CDKN2A CDKN2B EGFR PDGFRA PTEN TP53
3
Gastric cancer 37
Show member pathways
 12.66 CDKN2A CDKN2B EGFR PTEN TP53
4
Glioma 37
Show member pathways
 12.54 CDKN2A CDKN2B CDKN2C EGFR PDGFRA PTEN
5
Neuroscience 4
12.49 ENO2 GFAP MBP NKX2-2 SYP
6
MicroRNAs in cancer 37
12.41 CDKN2A EGFR PDGFRA PTEN TP53
7
DNA Damage 4
12.39 CDKN2A CDKN2C MGMT TP53 TP73
8
Cushing syndrome 37
Show member pathways
 12.33 CDKN2A CDKN2B CDKN2C EGFR
9
DNA Damage Response 1
Show member pathways
 12.29 CDKN2A PTEN TP53 TP73
10
Cell cycle 1 37
12.27 CDKN2A CDKN2B CDKN2C TP53
11
Human T-cell leukemia virus 1 infection 37
12.26 CDKN2A CDKN2B CDKN2C PDGFRA TP53
12
Cyclins and Cell Cycle Regulation 64
Show member pathways
 12.25 CDKN2A CDKN2B CDKN2C TP53
13
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.11 EGFR PDGFRA PTEN TP53
14
Cellular senescence (KEGG) 37
12.08 CDKN2A CDKN2B PTEN TP53
15
AKT Signaling Pathway 67
12.04 EGFR PDGFRA PTEN TP53
16
Direct p53 effectors 1
11.97 EGFR PTEN TP53 TP73
17
Spinal Cord Injury 1
11.87 EGFR GFAP MBP TP53
18
DNA Damage Response (only ATM dependent) 1
11.84 CDKN2A PTEN TP53 TP73
19
Small cell lung cancer 37
11.78 CDKN2B PTEN TP53
20
Neural Crest Differentiation 1
11.74 GFAP MBP OLIG1 OLIG2
21
Bladder cancer 37 1
11.64 CDKN2A EGFR TP53
22
Glioblastoma Multiforme 64
11.48 CDKN2A EGFR MGMT PDGFRA PTEN TP53
23
Integrated Cancer Pathway 1
11.41 CDKN2B PTEN TP53
24
Photodynamic therapy-induced AP-1 survival signaling. 1
11.38 CDKN2A EGFR PDGFRA TP53
25
Central carbon metabolism in cancer 37
11.37 EGFR IDH1 PDGFRA PTEN TP53
26
Oncogene Induced Senescence 66
11.06 CDKN2A CDKN2B CDKN2C TP53
27
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11 GFAP NKX2-2 OLIG1 OLIG2 PDGFRA SYP
28
TP53 Network 1
Show member pathways
 10.92 CDKN2A TP53 TP73
29
Cytosine methylation 1
Show member pathways
 10.75 IDH1 IDH2
Sources

GO Terms for Oligodendroglioma

About this section

Cellular components related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 CDKN2A CDKN2B CDKN2C EGFR MBP MGMT

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.92 CDKN2A CDKN2B CDKN2C PTEN TP53
2 negative regulation of neuron differentiation GO:0045665 9.69 NKX2-2 OLIG2 TP73
3 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.67 CDKN2B CDKN2C PTEN
4 oligodendrocyte differentiation GO:0048709 9.58 CDKN2C OLIG1 OLIG2
5 replicative senescence GO:0090399 9.57 CDKN2A TP53
6 negative regulation of telomerase activity GO:0051974 9.56 POT1 TP53
7 NADP metabolic process GO:0006739 9.55 IDH1 IDH2
8 cell cycle arrest GO:0007050 9.55 CDKN2A CDKN2B CDKN2C TP53 TP73
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 EGFR TP53
10 positive regulation of oligodendrocyte differentiation GO:0048714 9.5 NKX2-2 OLIG2 TP73
11 isocitrate metabolic process GO:0006102 9.48 IDH1 IDH2
12 spinal cord oligodendrocyte cell differentiation GO:0021529 9.46 NKX2-2 OLIG2
13 spinal cord oligodendrocyte cell fate specification GO:0021530 9.43 NKX2-2 OLIG2
14 negative regulation of phosphorylation GO:0042326 9.43 CDKN2A CDKN2B CDKN2C
15 glyoxylate cycle GO:0006097 9.37 IDH1 IDH2
16 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT NKX2-2 PTEN
17 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.92 CDKN2A CDKN2B CDKN2C PTEN

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 EGFR GFAP IDH1 PTEN SYP TP53
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH1 IDH2
3 protein kinase binding GO:0019901 9.17 CDKN2A CDKN2B CDKN2C EGFR PTEN TP53
4 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CDKN2A CDKN2B CDKN2C
Sources

Sources for Oligodendroglioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....